VKTX

Over the past six months, Viking Therapeutics reported its Fourth Quarter and Year-End 2025 financial results in February 2026 and First Quarter 2026 financial results on April 29, 2026. The stock experienced a decline of over 3% on the day of its Q1 2026 earnings report, and was down over 14% in 2026 despite encouraging progress in its clinical trials. The company has also announced participation in various investor conferences. Positive news included the completion of enrollment in the Phase 3 VANQUISH-1 and VANQUISH-2 trials for subcutaneous VK2735 in obesity. Data from a Phase 2 VENTURE-Oral trial of VK2735 and participant characteristics from the Phase 3 VANQUISH-1 trial were presented at the European Congress on Obesity (ECO) 2026 in May 2026. Analysts have a consensus price target for VKTX that suggests a potential return of over 200%.